Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Immunoproliferative Disorders 1Immune System Diseases 1

Interventions

Cyclophosphamide 12Rituximab 10Peripheral Blood Stem Cell Transplantation 8fludarabine phosphate 7Etoposide 5fludarabine 4Radiotherapy 4Filgrastim 4Cytarabine 4venetoclax 3ofatumumab 3Whole-Body Irradiation 3Vincristine 3Tacrolimus 3Mycophenolic Acid 3Methotrexate 3Doxorubicin 3Cyclosporine 3Carmustine 3Bendamustine Hydrochloride 3sargramostim 2romidepsin 2idelalisib 2ibrutinib 2ibritumomab tiuxetan 2Saline Solution 2Prednisone 2Pentetic Acid 2Ondansetron 2O(6)-benzylguanine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, Non-Hodgkin × cirmtuzumab × Clear all
NCT05431179 2023-04-21

A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Oncternal Therapeutics, Inc

Phase 3 Withdrawn
Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡